Key result
Optimal oral pharmacotherapy, including antiplatelet agents, antihypertensives, statins, and glycemic control, is essential for secondary stroke prevention and provides pleiotropic benefits.
Why the study?
What are the pleiotropic effects of optimal oral pharmacotherapy in the secondary prevention of stroke?
What are the pleiotropic effects of optimal oral pharmacotherapy in the secondary prevention of stroke?
Optimal oral pharmacotherapy for secondary stroke prevention may offer additional benefits through pleiotropic effects beyond their primary mechanisms of action.
Answers are grounded in this paper and cite their sources.
May support pleiotropic benefits of standard therapies in secondary stroke prevention; leaves open prospective trials to quantify incremental effects.
Stroke is a major cause of mortality and disability worldwide. During the past three decades, major advances have occurred in secondary prevention, which have demonstrated the broader potential for the prevention of stroke. Risk factors for stroke include previous stroke or transient ischemic attack, hypertension, high blood cholesterol and diabetes. Proven secondary prevention strategies are anti-platelet agents, antihypertensive drugs, statins and glycemic control. In the present review, we evaluated the secondary prevention of stroke in light of clinical studies and discuss new pleiotropic effects beyond the original effects and emerging clinical evidence, with a focus on the effect of optimal oral pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Kikuchi et al. (2012) conducted a review in Stroke (secondary prevention). Oral pharmacotherapy (antiplatelets, antihypertensives, statins, glycemic control) was evaluated. Optimal oral pharmacotherapy, including antiplatelet agents, antihypertensives, statins, and glycemic control, is essential for secondary stroke prevention and provides pleiotropic benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: